investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Molecular mechanisms of B cell malignant transformation
Ping Xie
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Ping Xie
Rutgers University
New Brunswick, United States
Related projects
Michelle S Bradbury
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra
Melanoma of skin
Palliative Care
Damien Garbett
Identification of mechanisms involved in coordinated group migration
Melanoma of skin
Jennifer L Guerriero
Harnessing anti-tumor macrophages for cancer therapy
Melanoma of skin
Bin Tian
Illumina NextSeq500 DNA Sequencing System
Melanoma of skin
Meenhard F Herlyn
Human Melanoma: Etiology, Progression and Therapy
Melanoma of skin
Pathology
Titia De Lange
The role of telomere-related tetraploidization in cancer
Melanoma of skin
David A Scheinberg
Mechanisms of action of a TCR-like antibody to WT1
Leukaemia
Eric S Lander
Large Scale Sequencing and Analysis of Genomes
Melanoma of skin
Kimberly Stegmaier
Validating Syk as a Target for AML Therapy
Leukaemia